{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-24-000120","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2024-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.754495+00:00","generated_at":"2026-06-01T07:42:49.611121+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Zentalis appoints Luke Walker, M.D. to board, expanding to 7 directors","bullets":["Board increased from 6 to 7 members; Dr. Walker appointed as Class II director effective May 24, 2024.","Term runs until 2025 annual meeting; Dr. Walker also joins Audit Committee.","Initial RSU grant of 72,481 shares valued at $850,000, vesting over 3 years.","Annual retainer for board service $45,000 plus $10,000 for Audit Committee membership.","Standard indemnification agreement signed; annual equity grants after 6 months service."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-24-000120","json":"https://secwatch.observer/filing/0001725160-24-000120.json","markdown":"https://secwatch.observer/filing/0001725160-24-000120.md","text":"https://secwatch.observer/filing/0001725160-24-000120.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000120/0001725160-24-000120-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000120/zntl-20240524.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:42:49.611121+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68a86a2e47","claim":"Luke Walker, M.D. was appointed as Director at Zentalis Pharmaceuticals, Inc..","evidence_excerpt":"On and effective May 24, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) increased its size from six to seven directors and appointed Luke Walker, M.D., as a Class II director.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000120/0001725160-24-000120-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}